-
Study aim
-
Determination of the efficacy of topiramate in comparison with acetazolamide in mean and standard deviation of infant head circumference with external hydrocephalus
-
Design
-
A clinical trial study, with parallel groups, randomized into two age-matched groups on 50 infants between 3 and 9 months of age with external hydrocephalus
-
Settings and conduct
-
The study was performed on 50 infants with external hydrocephalus who referred to Shahid Beheshti Hospital in Kashan and Qom Children and were definitively diagnosed by clinical examination, head circumference measurement and sonography. At first, 2 weeks Given the opportunity and acceleration of growth around infants, if they are abnormal, they will be treated. Patients are divided into two groups. The first group received acetazolamide from Iran Daru Company and the second group received topiramate from Sobhan Company. At the end of each month, the head circumference is measured, and at the end of the 2-month treatment period, patients undergo Brain Sonography. One month after the end of the 2-month drug intervention, patients are evaluated for external hydrocephalus.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria are normal development and criteria for diagnosing external hydrocephalus based on clinical evidence and imaging studies and negation of other major causes of head circumference (no brain tumor, internal hydrocephalus, subdural hematoma and symptoms of increased ICP).
Exclusion criteria: having a brain tumor and subdural hematoma, symptoms of increased intracranial pressure,
Abnormal cognitive motor development, the presence of internal hydrocephalus
-
Intervention groups
-
The first group receives acetazolamide from Iran Daru Company and the second group receives topiramate from Sobhan Company
-
Main outcome variables
-
Head circumference, motor developmental status, fontanel size, fontanel position, case group